Ultragenyx Pharmaceutical must file required documents regarding its NASDAQ company status with the SEC.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ultragenyx Pharmaceutical must file required documents regarding its NASDAQ company status with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Lunai Bioworks Inc. failed Nasdaq listing requirements and plans to file Form 25.
- Zhibao Technology traded shares on Nasdaq and filed a report with the Securities and Exchange Commission on October 8, 2026.
- Linde PLC filed reports with the Securities and Exchange Commission and was listed on the Nasdaq stock exchange.
- An SEC filing was made on August 4, 2026, relating to an ETF listed on Nasdaq.
- SPACSphere Acquisition Corp. units traded on Nasdaq and filed required 13F disclosures with the SEC.